Investigators are optimistic about sustained-release ranibizumab delivery based on the phase II LADDER study. Learn what this means for patients with neovascular AMD.
In Part 2 of this EyePod episode, Rohit Varma, MD, continues the discussion on artificial intelligence (AI) and its increasing presence in diabetic retinopathy (DR) and glaucoma—and at the podium.
In a placebo-controlled phase II study of patients with severe non-infectious uveitis involving the posterior segment, subcutaneous sarilumab demonstrated promising therapeutic activity.
This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.
This email was sent by: %%Member_Busname%% %%Member_Addr%% %%Member_City%%, %%Member_State%%, %%Member_PostalCode%%, %%Member_Country%%
